Related Experiment Video
Updated: Dec 8, 2025
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Pediatric multiple sclerosis - current status of epidemiology, diagnosis and treatment
Waldemar Brola1, Barbara Steinborn2
1Collegium Medicum, Jan Kochanowski University in Kielce. wbrola@wp.pl.
Insights
Paediatric multiple sclerosis (MS) affects children and adolescents, presenting milder but potentially disabling courses. Recent advances improve diagnosis and treatment, though further research is needed.
Area of Science:
- Neurology
- Immunology
- Paediatrics
Background:
- Multiple sclerosis (MS) is a central nervous system inflammatory demyelinating disease primarily affecting young adults.
- Paediatric MS (PMS), with symptom onset before age 18, accounts for 3-5% of MS cases.
- PMS shares similarities with adult MS but exhibits distinct epidemiological and clinical features.
Purpose of the Study:
- To review the current understanding of paediatric multiple sclerosis (PMS).
- To discuss the epidemiology, pathophysiology, diagnosis, and treatment of MS in children.
- To highlight advancements and remaining research needs in PMS.
Main Methods:
- Literature review of recent studies on paediatric MS.
- Analysis of epidemiological data, diagnostic criteria, and therapeutic approaches.
- Synthesis of current knowledge on PMS management.
Main Results:
- Paediatric MS typically follows a relapsing-remitting course (95-98%) with a milder overall course than adult MS, yet can cause significant early disability.
- Differential diagnosis in children includes other demyelinating diseases, metabolic disorders, and neuroborreliosis, with acute disseminated encephalomyelitis (ADEM) being a key diagnostic challenge.
- Significant progress in PMS understanding has led to earlier diagnosis, updated criteria, and increased availability of disease-modifying therapies (DMTs) for children.
Conclusions:
- Understanding of paediatric MS has expanded significantly over the last decade.
- Earlier diagnosis and treatment initiation with DMTs are crucial for managing PMS.
- Further research is essential to address remaining knowledge gaps in paediatric MS.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that mostly affects younger adults. However, the first symptoms of MS can appear in children and adolescents before the age of 18, and we call this paediatric MS (PMS). It is estimated that paediatric MS accounts for 3-5% of the general population of patients with MS. Despite the fundamental si-milarities to adult MS, PMS has many distinctive features. Paediatric MS has a milder course compared to adults, but leads to sig-nificant disability at an early age. PMS is relapsing-remitting in 95-98% of cases; the primary progressive manifestation is much less common than in adults. The differential diagnosis of MS in children should include other childhood demyelinating diseases, mitochondrial and metabolic diseases, connective tissue diseases, and neuroborreliosis. Differentiating acute disseminated en-cephalomyelitis (ADEM) from the first onset of MS remains the biggest challenge. Over the past 10 years, understanding of the epidemiology, pathophysiology, diagnosis, and treatment of MS in children has significantly expanded. The diagnostic criteria leading to earlier diagnosis and initiation of disease-modifying therapy (DMT) have changed, and the number of drugs used in children has increased. However, many important issues require further research. This review discusses the current state of knowledge regarding the epidemiology, diagnosis, and treatment of multiple sclerosis in children.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism